Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Novartis AGNYSE: NVS

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow grows, but more slowly than its trailing trend

Q2 FY2026 investing cash flow of $3.09B (cash outflow) rose 37.8% year over year, behind the +234.5% change in trailing-twelve-month investing cash flow. Sequentially, it fell 73.7% from the prior quarter.

Context

  • Investing cash flow amounted to 8.9% of revenue in FY2025, down 5.6 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +37.8% toward the trailing-twelve-month pace of +234.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$3.09B-73.7% QoQ
Last fiscal yearDec 2025
-$4.9B-34.8% YoY
LTMJun 2026
-$17.8B+234.5% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.8%——
1 year-34.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(4.9B) USD
Year-over-year change
+34.8%

Investing Cash Flow vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +234.5% is the 4th highest of 11, against a peer median of +57.1%.
  • Investing cash flow amounts to 32.0% of revenue for NVS, versus a peer median of 16.9%.
NVS Competitors
Investing Cash Flow for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 82.71B DKK-37.8%+47.0%25.1%
MRKMerck & Co., Inc.LTM Jun 2026$27.3B USD+261.7%+40.4%41.1%
NVSNovartis AGLTM Jun 2026$17.8B USD+234.5%—32.0%
SNYSanofiLTM Jun 2026€16.54B EUR+2030.8%+10.0%33.8%
GILDGilead Sciences, Inc.LTM Jun 2026$10.84B USD+212.7%+24.8%35.6%
JNJJohnson & JohnsonLTM Sep 2026$9.34B USD-54.2%+24.0%9.4%
AZNAstraZeneca PLCLTM Sep 2026$8.16B USD+24.7%+32.0%13.1%
GSKGSK plcLTM Jun 2026£6.86B GBP+89.5%-19.3%20.7%
ABBVAbbVie Inc.LTM Jun 2026$6.5B USD-46.1%+120.1%10.1%
PFEPfizer Inc.LTM Jun 2026$5.69B USD-260.4%-55.9%8.9%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$4.91B USD+253.6%+57.3%10.0%
Peer median (excluding NVS) —+57.1%+28.4%16.9%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income22.91B6.05B8.57B11.94B14.06B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
Deferred Income Tax1.63B1.13B551M1.7B(361.84M)
Stock-Based Compensation700M791M865M1.04B0
Change in Working Capital(73M)(796M)(369M)(706M)(3.08B)
Accounts Receivables(352M)(397M)(1.5B)(931M)(1.13B)
Inventory(102M)(560M)(546M)(225M)34.17M
Accounts Payables(111M)(181M)479M(105M)(274.4M)
Other Working Capital492M342M1.2B555M(1.71B)
Other Non-Cash Items(15.68B)359M(3.44B)(2.43B)3.27B
Operating Cash Flow15.07B14.24B14.46B17.62B19.24B
Capital Expenditures(2.56B)(2.24B)(2.75B)(3.81B)(1.56B)
Acquisitions (Net)20.46B(864M)(3.57B)(3.83B)(3.01B)
Purchases of Investments(16.59B)(34.81B)(747M)(3.65B)(304.55M)
Sales of Investments2.74B39.49B11.6B3.7B2.19B
Other Investing Activities(1.34B)(1.43B)(624M)(2.38B)140.72M
Investing Cash Flow4.21B1.47B5.6B(7.51B)(4.9B)
Debt Repayment(5.67B)(2.59B)(1.94B)4.39B2.72B
Common Stock Issued000027.14M
Common Stock Repurchased(3.06B)(10.65B)(8.72B)(8.33B)(9.26B)
Dividends Paid(7.37B)(7.51B)(7.26B)(7.62B)(7.86B)
Other Financing Activities(169M)181M3.63B(177M)(577.95M)
Financing Cash Flow(16.26B)(20.56B)(14.28B)(11.74B)(14.94B)
Effect of Forex Changes(266M)(32M)100M(298M)579.07M
Net Change in Cash2.75B(4.89B)5.88B(1.93B)(24M)
Free Cash Flow12.52B12B11.71B13.81B17.69B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.